Novartis’ $8.7bn AveXis deal shows gene therapy appeal – Chemistry World
|
Novartis' $8.7bn AveXis deal shows gene therapy appeal
Chemistry World This is Novartis' second deal related to an AAV-based gene therapy. In January, it licensed marketing rights for Luxturna from Philadelphia, US-based Spark Therapeutics for $105 million up front and up to $65 million in milestone payments. In December … Worldwide Cancer Gene Therapy Market Overview, Region Wise Analysis of Top Players and Feasibility Studies 2023 Cancer Gene Therapy Market to Record an Exponential CAGR by 2025 |
